Paolo Carlini
Yahoo!
145 Papers
1.5K Citations
Paolo Carlini is an academic researcher from Yahoo!. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 32, co-authored 141 publications.
Chat about Author
Papers
Adherence to hormone therapy in patients with mCRPC: psychometric validation of the A-HT questionnaire.
Laura Iacorossi,Francesca Gambalunga,Michela Piredda,Irene Terrenato,Carla Marzo,Redes Escolares de América Latina,Ippolito Notarnicola,Tatiana Bolgeo,Maria Grazia De Marinis,Paolo Carlini +9 more
TL;DR: In this article , a self-report questionnaire was developed and validated with women with breast cancer treated with oral hormonal therapies (A-BET) to test the psychometric properties of this instrument on patients with mCRPC treated with Abiraterone Acetate (AA) or Enzalutamide (ENZ).
Does Granulocyte Colony-Stimulating Factor Worsen Anemia in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide?
Paola Papaldo,Gianluigi Ferretti,Serena Di Cosimo,Diana Giannarelli,Paolo Marolla,Massimo Lopez,Enrico Cortesi,Mauro Antimi,Edmondo Terzoli,Paolo Carlini,Patrizia Vici,Claudio Botti,Luigi Di Lauro,Giuseppe Naso,Cecilia Nisticò,Marcella Mottolese,Franco Di Filippo,Enzo Maria Ruggeri,Anna Ceribelli,Francesco Cognetti +19 more
TL;DR: The data suggest that a G-CSF dose-related effect may play a role in worsening anemia in patients receiving adjuvant EC.
Impact of Clinical Response to Neoadjuvant Chemotherapy in the Era of Robot Assisted Radical Cystectomy: Results of a Single-Center Experience.
Umberto Anceschi,Aldo Brassetti,Gabriele Tuderti,M. Ferriero,Manuela Costantini,A.M. Bove,Fabio Calabrò,Paolo Carlini,Sabrina Vari,Riccardo Mastroianni,Michele Gallucci,Giuseppe Simone +11 more
TL;DR: Complete response to NACT is associated with increased OS probability, but significant nodal residual disease remains the only independent predictor of OS after RARC.
Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide
Paola Papaldo,Massimo Lopez,Paolo Marolla,Enrico Cortesi,Mauro Antimi,Edmondo Terzoli,Patrizia Vici,Carlo Barone,Gianluigi Ferretti,Serena Di Cosimo,Paolo Carlini,Cecilia Nisticò,Francesca Conti,Luigi Di Lauro,Claudio Botti,Francox Di Filippo,Alessandra Fabi,Diana Giannarelli,Federico Calabresi +18 more
TL;DR: In the adjuvant setting, the frequency of prophylactic G-CSF administration during EC could be curtailed to only two administrations without altering outcome and this nonrandomized trial design provides support for evaluating alternative, less intense G- CSF schedules for women with early breast cancer.